April 8, 2024 — Implantation of the Impella CP micro-axial flow pump in the hours after a heart attack significantly increased the rate of survival at six months among people suffering cardiogenic ...
Cardiogenic Shock
This page includes content on technologies to treat cardiogenic shock, including percutaneous ventricular assist devices (pVAD), intra-aortic balloon pumps (IABP) and extracorporeal membrane oxygenation (ECMO). This condition occurs when the heart can no longer pump enough oxygenated blood to the body. The most common cause of cardiogenic shock is damage to the heart from a severe heart attack. The standard of care for this condition for more than 20 years has a 50 percent survival rate, but improvements have recently been seen in studies using early pVAD intervention prior to percutaneous coronary intervention (PCI). For more information, visit the National Institute of Health (NIH) cardiogenic shock information page.
-
-
September 22, 2022 — Abiomed (ABMD) announces the result of a three-year, investigator-led study of all Impella-supported patients treated at 109 hospitals in Japan shows a 30-day survival rate of 77% ...
-
September 16, 2022 — Abiomed announced two approvals from the U.S. Food and Drug Administration (FDA) related to clinical research of Impella heart pumps in acute myocardial infarction (AMI) ...
-
March 31, 2022 – Windtree Therapeutics, a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced it has ...
April 8, 2024 — Implantation of the Impella CP micro-axial flow pump in the hours after a heart attack significantly ...
April 08, 2024
October 26, 2023 — A new study presented at TCT 2023 revealed inequities in access to mechanical circulatory support in ...
October 25, 2023
April 28, 2023 — Windtree Therapeutics, Inc. is a biotechnology company focused on advancing late-stage interventions ...
April 28, 2023
March 22, 2023 — Windtree Therapeutics, Inc., a biotechnology company focused on advancing multiple late-stage ...
March 22, 2023
March 15, 2023 — Windtree Therapeutics, Inc, a biotechnology company focused on advancing late-stage interventions for ...
March 15, 2023
November 7, 2022 — The immediate use of veno-arterial mechanical circulatory extracorporeal membrane oxygenation (ECMO) ...
November 07, 2022
October 21, 2022
October 20, 2022 — Cardiogenic shock—a life threatening condition when a person’s heart can’t pump enough blood to meet ...
October 20, 2022
September 27, 2022 — Windtree Therapeutics, Inc., a biotechnology company focused on advancing multiple late-stage ...
September 27, 2022
September 22, 2022 — Abiomed (ABMD) announces the result of a three-year, investigator-led study of all Impella ...
September 22, 2022
September 20, 2022 — An analysis from the Society of Thoracic Surgeons/American College of Cardiology(STS/ACC) TVT ...
September 20, 2022
September 19, 2022 — Supira Medical, Inc., a Shifamed portfolio company focused on developing the next-generation ...
September 19, 2022
September 16, 2022 — Abiomed announced two approvals from the U.S. Food and Drug Administration (FDA) related to ...
September 16, 2022
September 2, 2022 — Acetazolamide added to intravenous loop diuretics decreases congestion within three days in patients ...
September 02, 2022
June 1, 2022 — Recardio's Phase 2 trial results demonstrated the excellent safety profile of its lead drug Dutogliptin ...
June 01, 2022